AstraZeneca inhaler Breztri for lung disorder launched in Canada
Roland Magnusson/iStock Editorial via Getty Images


AstraZeneca (NASDAQ:AZN) on Monday said that its inhaler Breztri Aerosphere was now available in Canada after Health Canada's approval.
Breztri (budesonide/glycopyrronium/formoterol fumarate dihydrate) is indicated as a long-term maintenance therapy to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA.

Health Canada's approval was backed by positive data from phase 3 trials â ETHOS and KRONOS.
COPD is a chronic disease which can cause obstruction of airflow in the lungs leading to breathing difficulty, among other symptoms.